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The NF-κB signaling pathway is known to play an important role in the regulation of
osteoclastic bone resorption and cancer cell growth. Previous studies have shown
that genetic inactivation of IκB kinase (IKK), a key component of NF-κB signaling,
inhibits osteoclastogenesis, but the effects of pharmacologic IKK inhibitors on
osteolytic bone metastasis are unknown. Here, we studied the effects of the IKK
inhibitors celastrol, BMS-345541, parthenolide, and wedelolactone on the
proliferation and migration of W256 cells in vitro and osteolytic bone destruction in
vivo. All compounds tested inhibited the growth and induced apoptosis of W256 cells
as evidenced by caspase-3 activation and nuclear morphology. Celastrol,
BMS-345541, and parthenolide abolished IL1β and tumor necrosis factor α–induced
IκB phosphorylation and prevented nuclear translocation of NF-κB and DNA binding.
Celastrol and parthenolide but not BMS-345541 prevented the activation of both
IKKα and IKKβ, and celastrol inhibited IKKα/β activation by preventing the
phosphorylation of TAK1, a key receptor–associated factor upstream of IKK. Celastrol
and parthenolide markedly reduced the mRNA expression of matrix
metalloproteinase 9 and urinary plasminogen activator, and inhibited W256
migration. Administration of celastrol or parthenolide at a dose of 1 mg/kg/day
suppressed trabecular bone loss and reduced the number and size of osteolytic bone
lesions following W256 injection in rats. Histomorphometric analysis showed that
both compounds decreased osteoclast number and inhibited bone resorption. In
conclusion, pharmacologic inhibitors of IKK are effective in preventing osteolytic
bone metastasis in this model and might represent a promising class of agents to the
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